Aptinyx Inc. (APTX)
| Market Cap | 273.90M |
| Revenue (ttm) | 2.48M |
| Net Income (ttm) | -52.34M |
| Shares Out | 46.98M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $4.07 |
| Previous Close | $4.33 |
| Change ($) | -0.26 |
| Change (%) | -6.00% |
| Day's Open | 4.50 |
| Day's Range | 3.93 - 4.52 |
| Day's Volume | 4,378,664 |
| 52-Week Range | 1.81 - 5.03 |
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatme...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymo...
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
Investors reacted negatively to the company's announcement of a secondary stock offering.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today a...
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...
Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma
Data readout expected by late 2020 Data readout expected by late 2020
Is (APTX) Outperforming Other Medical Stocks This Year?
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
As of late, it has definitely been a great time to be an investor in Aptinyx.
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020
Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for May 6th
Relative underperformance compared to the large caps, a super-dovish Fed and the U.S. government's gigantic aid toward small-and-mid-cap stocks have boosted pint-sized stocks lately.
As of late, it has definitely been a great time to be an investor Aptinyx
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2019 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.51% and -2.96%, respectively, for the quarter ended December 2019.
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease NYX-458 is currently under evaluation in a Phase 2 study...
Shares rose in response to news that a large investment management company has purchased a significant ownership position.
Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and ne...
About APTX
Aptinyx, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to tr... [Read more...]
| Industry Biotechnology | IPO Date Jun 21, 2018 |
| CEO Dr. Norbert G. Riedel | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol APTX |
Financial Performance
In 2019, Aptinyx's revenue was $3.67 million, a decrease of -44.19% compared to the previous year's $6.57 million. Losses were -$57.41 million, 7.75% more than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for Aptinyx stock is "Buy." The 12-month stock price forecast is 10.71, which is an increase of 163.14% from the latest price.